This site is for U.S. Healthcare Providers only.
Please try after sometime.
The projects featured below are designed to address barriers in cardiometabolic care by either demonstrating effectiveness of implementation strategies
or scaling strategies to other health systems.
For more information about the projects, please reach out to the corresponding author in the publication or to the project contact.
HEARTWISE-ASCVD
Implementation of opportunistic AI-based coronary artery calcium screening
Learn more about the HEARTWISE-ASCVD project
Evaluate how opportunistic AI-based coronary artery calcium (CAC) screening plus notification affects lipid-lowering
therapy (LLT) and low-density lipoprotein-cholesterol (LDL-C) levels in patients with a positive CAC score, while assessing its
impact on downstream healthcare utilization patterns.
Prompts/Reminders: Notify the clinician and the patient about CAC significance using an image of calcified plaque with
recommendations for risk discussions, lipid testing, and LDL-C/LLT goals. Follow-up with the clinician and patient at month 2
if no change.
Education: Clinician facilitation and education via evidence-based treatment workflows based on ACC/AHA guidelines, ACC
Expert consensus pathways and institutional treatment guidelines.
Audit/Feedback: Provide feedback of LDL-C control via primary care reports
Motivation: Encourage patients and clinicians to act on results.
PROMPT-Lipid Multicenter Registry Study
Pragmatic trial of messaging to providers about treatment of HyperLIPIDemia
Learn more about the PROMT-LIPID Multicenter Registry
Study
Promote guideline-concordant, high value, quality care for patients with very-high risk atherosclerotic cardiovascular disease (VHR
ASCVD) by implementing the PROMPT-LIPID Toolkit across eight study sites committed to leveraging computerized decision
support (CDS) tools. Additionally, create a centralized, deidentified data repository of real-world lipid-lowering therapy (LLT)
treatment and low-density lipoprotein cholesterol (LDL-C) monitoring practices for VHR ASCVD patients to facilitate collaborative
quality improvement efforts amongst health system stakeholders.
LLT intensification at 6 months and 2 years
LDL-C goal <70 mg/dL
LDL-C goal <55 mg/dL
This is a collaborative study between a LATTICE™ Consortium Expert and Amgen.
Corrie Lipids
Examining real-world implementation of the patient-centered Corrie Lipids program
Learn more about the Corrie Lipids Program
Implement a scalable and evidence-based Corrie Lipids Program (Corrie Health, Inc) to increase low-density lipoprotein
cholesterol (LDL-C) awareness, treatment, and achievement of guideline-directed management.
Examine real-world implementation of the patient-centered Corrie Lipids Program guided by the implementation science
framework, RE-AIM (reach, effectiveness, adoption, implementation, maintenance)
Patient-facing app: Embedded clinical decision support with patient education to improve awareness of LDL-C goals along
with empowering action to adhere to lipid lowering therapies (LLT)
Clinician-focused education: Educational training session on cholesterol management defined by AHA/ACC/Multi-society
Guidelines and ACC Expert Consensus Decision Pathway
Virtual cholesterol management: Activating patients to know their LDL-C levels and engage in shared decision-making
about LLT with their clinicians
Guideline-based LDL-C testing: LDL-C is measured at baseline and repeated in 4-12 weeks if LLT is started or intensified
LDL-C test completion
LDL-C attainment at 6 months
Guideline-directed medical therapy (GDMT) LLT use
Patient activation*
*Patient activation is the process of actively involving patients in their own healthcare including shared decision-making, self-management, and partnering with HCPs
Identifying and engaging clinicians and their high-risk patients who have an indication for LLT intensification to achieve
recommended LDL-C levels
CHA Test to Treat
Implementation of a large-scale program to identify interventions that could impact patient treatment and adherence to
guideline-recommended lipid-lowering therapies
Learn more about the CHA Test to Treat Project
Implementation of a large-scale program to identify interventions that could impact patient treatment and adherence to
guideline-recommended lipid-lowering therapies (LLT). The program gathers data to identify how to improve quality of care
during hospitalization and through six months post-discharge among patients hospitalized for myocardial infraction (MI) or
percutaneous coronary intervention (PCI).
Inpatient intervention: Increase low-density lipoprotein cholesterol (LDL-C) testing and identification of evidence-based LLT
as appropriate before discharge
Outpatient intervention: Increase repeat LDL-C testing; Identification of evidence-based LLT as appropriate to reach
recommended LDL-C thresholds (registered nurse remotely coordinates care to help ensure repeat LDL-C
testing and LLT adherence)
Increase LDL-C testing rates
Improve GDMT
Improve outpatient follow-up rates
Increase achievement of LDL-C recommended levels
For sites/systems to be eligible for project participation, they must be a member of the CardioHealth Alliance
This is a LATTICE™ Consortium expert’s independent project that is sponsored by Amgen.
CMCA Project
Determine the effectiveness of holistic, patient-centered, team-based coordinated care for cardiometabolic disease
Learn more about the CMCA Project
Determine the effectiveness of the holistic, patient-centered, team-based care coordinated approach to cardiometabolic disease
and improve the way care is delivered to this high-risk patient population including patients with ASCVD at four
key practice settings across the U.S. Advanced practice providers (APPs) and pharmacists (PharmDs) are extenders of care that
can support the primary care provider (PCP) care for patients.
Equip APPs or PharmDs to champion CMCA protocols and care model embedded within primary care
Demonstrate the effectiveness of a holistic, team-based care model and impact to cardiometabolic metrics:
LDL tests ordered
LDL tests completed
Repeat LDL tests
Average LDL trends
Percent of patients that achieve LDL target
This is a LATTICE™ Consortium expert’s independent project that is sponsored by Amgen.
cvMOBIUS2
Prospective study leveraging electronic health record system to examine lipid-lowering therapy utilization and LDL-C levels
Learn more about the cvMOBIUS2 project
Examine and track lipid-lowering therapy (LLT) utilization and low-density lipoprotein cholesterol (LDL-C) levels in adults
with atherosclerotic cardiovascular disease (ASCVD) seen across a maximum of 25 health systems over 5 years. Annual sub-
analysis will evaluate factors associated with achievement of appropriate LDL-C lowering in various cohorts of adults with
ASCVD.
Prospective registry study leveraging Patient-Centered Clinical Research Network (PCORNET) electronic health record
(EHR) system to examine LLT utilization and LDL-C levels
Increase proportion of patients with ASCVD that are identified and, where appropriate, treated according to ACC/AHA
guideline recommendations for LLT
Understand baseline characteristics of people with established ASCVD who initiate non-statin LLTs versus those who
don’t initiate non-statin LLTs
Improve clinical outcomes in adults by LDL-C level at baseline and over time
Understand health system heterogeneity of utilization of non-statin LLTs
Track lipid trajectories in patients with ASCVD by treatment status
Recognize novel patterns in LLT uptake
This is a collaborative study between a LATTICE™ Consortium Expert and Amgen.
LOGAN-CV
Evaluate a multifaceted intervention on clinician knowledge, attitudes, beliefs, and practices for guideline-based medical therapy
Learn more about the LOGAN-CV project
Evaluate the impact of a multifaceted intervention – consisting of a performance dashboard, clinician education modules,
patient engagement materials, monthly newsletters, and live peer-to-peer discussion calls – on clinician knowledge-
attitudes-beliefs (KAB) and practices as compared to guideline recommendations for adult patients with recent myocardial
infarction (MI) and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL on a statin.
Equip clinicians with multifaceted tools to help improve adherence to guideline-based recommendations
Education modules and peer-to-peer discussion calls
Online performance platform dashboard with a tailored summary of the patients’ lipid management
Increase proportion of patients with LDL-C <70 mg/dL achieved at any time during the 12-month intervention (primary)
Change in:
LLT intensification and titration
Guideline-aligned LDL-C testing
Clinicians’ knowledge, attitudes, and beliefs
Practices may be eligible to use the Premier Performance Dashboard if they are part of the Premier Network
ACC Driving Urgency to Treat LDL-C
Provide clinicians with tailored messages about guideline-directed medical therapy at the point of care
Learn more about the ACC Driving Urgency Project
Increase the rate of diagnostic screening of low-density lipoprotein cholesterol (LDL-C) in patients with and
without ASCVD to improve awareness and implementation of 2018 Guidelines on the Management of Blood
Cholesterol, and 2022 ACC Expert Consensus Decision Pathway (ECDP) at a national scale.
Equip cardiology and primary care clinics to deploy GDMT-related awareness communications and practice/patient-level
ASCVD dashboards using:
Veradigm Practice Fusion EHR system, a cloud-based EHR platform that provides reliable, secure access to information
Veradigm TouchPoint Media solution, a tool to reach targeted providers at the point-of-care
HealthPALS CLINT MAX system, an artificial intelligence platform to analyze patient data and identify actionable care gaps
Clinician engagement (message impressions, click through rates, dashboard sign-up, dashboard usage)
Improvements in lipid testing
Lipid treatment in patients with hypercholesterolemia and ASCVD patients
Practice eligibility for project based on:
EHR = electronic health record; GDMT = guideline-directed medical therapy
1. Data on file, Amgen; 2022. 2. Shah NN, et al. American Heart Journal. 2022;253:76-85. 3. Magnussen, et al. N Eng J Med. 2023;389(14):1273-85. 4. American Heart Association. My
LDL-C Cholesterol Guide. www.heart.org. Accessed August 15, 2025. 5. Heart Disease Risk Factors. www.cdc.gov. Accessed August 15, 2025.
This is a LATTICE™ Consortium member’s independent project that is sponsored by Amgen.
We welcome ideas for improving patient care that are
rooted in implementation science. Click the button below,
make sure you understand the guidance and criteria, and
follow the 2-step submission process.
Reach us at LATTICEConsortium@amgen.com
to connect with peers and institutions who have
track records in implementation and scaling.
An American Journal of Managed Care Roundtable (Sponsored by Amgen)
Experts discuss implementation of science-based LATTICE™ initiatives, including LOGAN-CV, Cardiometabolic Center Alliance, and PROMPT-LIPID, and outline the benefits of leveraging EHR systems as a support tool for launching and scaling initiatives.
Experts provide strategies and best practices for engaging important stakeholders within health systems for buy-in on implementation science initiatives.
Our panel discusses methods to ensure the success of implementation science initiatives, including a strong system of measurement, a strategic communication plan, and preparedness to address challenges.
Implementation science experts explain approaches for scaling initiatives to more than one health system and discuss the future of LATTICE™ Consortium.
Thought leaders explain implementation science, explain how it can be applied to day-to-day clinical practice, and provide an overview of LATTICE™ Consortium.